Sodium‐glucose co‐transporter‐2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England-Reference-Cited by-同舟云学术

Sodium‐glucose co‐transporter‐2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England

Published:2018-04-17 Issue:7 Volume:20 Page:1659-1669
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Heald Adrian H.¹²^ORCID,Fryer Anthony A.³,Anderson Simon G.¹,Livingston Mark⁴,Lunt Mark¹,Davies Mark⁵,Moreno Gabriela Y. C.²⁶,Gadsby Roger⁷⁸,Young Robert J.⁸,Stedman Mike⁵

Affiliation:

1. School of Medicine Sciences and Manchester, Academic Health Sciences Centre University of Manchester Manchester UK

2. Department of Diabetes and Endocrinology Salford Royal Hospital Salford UK

3. Institute for Science & Technology in Medicine Keele UK

4. Department of Blood Sciences Walsall Manor Hospital Walsall UK

5. RES Consortium Andover UK

6. High Specialty Regional Hospital of Ixtapaluca Mexico City Mexico

7. Warwick Medical School University of Warwick Warwick UK

8. National Diabetes Audit London UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13281

Reference18 articles.

1. National Diabetes Audit 2013─2014 and 2014─2015. Health & Social Care Information Centre;2016.

2. Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson's disease

3. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: lessons from the UK National Diabetes Audit;Heald A;Diabetes Obes Metab,2017

4. National Health Service. GP practice prescribing. Leeds: NHS Digital;2017.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT-2 Inhibitors: Focus on Dapagliflozin;Cardiology in Review;2024-04-26

2. Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis;Cureus;2022-07-26

3. Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin;Cureus;2022-01-29

4. The right place for Sulphonylureas today: Part of ‘Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus’;Diabetes Research and Clinical Practice;2019-11

5. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study;Cardiovascular Diabetology;2019-09-24